Avid Bioservices Inc (CDMO)

[biopharm]

Just a small reply ? No stories ?

Oh... there are many stories, but I guess for now we can just stick with the PS Targeting leads to the statistical reduction of MDSC's and the reductions of MDSC's leads to a stronger, natural, optimal immune system and hmmmm, reversal of cancer...

Wistar and Swedish biopharm firm taking on cancer together
Apr 28, 2016, 11:17am EDT

The Wistar Institute, continuing its push to form industry alliances, has entered into a partnership with a Swedish biopharmaceutical company to explore new cancer treatment strategies.

The partnership with Cormorant Pharmaceuticals, of Sweden, will seek to combine Wistar’s new methods for analyzing tumor biopsies with Cormorant’s experimental cancer therapy HuMax-IL8, which is in early clinical testing at the National Cancer Institute.

Dr. Dmitry Gabrilovich, program leader of Wistar’s tumor immunology program, and his team at the Philadelphia research institution, have developed and validated a new biomarker that will show if a tumor is inhibiting the immune system’s response to the tumor by targeting the migration of myeloid cells to tumor tissues.

Myeloid cells are cells that make new red bloods cells and most types of white blood cells. Myeloid suppressor cells play an important role in the regulation of the body’s immune response to invading tumor cells.

Gabrilovich’s research has focused on abnormalities in the function of various myeloid suppressor cells.

“This partnership provides us with the opportunity to assess the clinical utility of our new detection method of myeloid-derived suppressor cells in tumors,” said Gabrilovich. “The evaluation of these cells directly in tumors is critically important for understanding the effect of the novel therapy developed by Cormorant.”

Heather A. Steinman, vice president for business development and executive director of technology transfer at Wistar Institute, said by working together the two organizations can pair Gabrilovich’s expertise with Cormorant’s new biologic candidate “to accelerate the development of cancer therapies while attaining the highest possible chance of successfully improving patient outcomes.”

http://www.bizjournals.com/philadelphia/news/2016/04/28/wistar-swedish-biopharm-fcormorant-cancer-tumors.html